We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

63 hedge funds and large institutions have $113M invested in Osiris Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

6% less funds holding

Funds holding: 6763 (-4)

10% less capital invested

Capital invested by funds: $126M → $113M (-$13.1M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

63% less call options, than puts

Call options by funds: $2.2M | Put options by funds: $5.92M

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
63
Holders Change
-4
Holders Change %
-5.97%
% of All Funds
1.82%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
23
Reduced
20
Closed
10
Calls
$2.2M
Puts
$5.92M
Net Calls
-$3.72M
Net Calls Change
-$159K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$29.4M
CCM
2
Consonance Capital Management
New York
$27M +$16.9M +1,079,008 +111%
BFA
3
BlackRock Fund Advisors
California
$11.6M +$688K +43,960 +5%
BIT
4
BlackRock Institutional Trust
California
$8.08M +$1.56M +99,997 +19%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.72M +$630K +40,285 +7%
BBA
6
Baker Bros. Advisors
New York
$4.75M -$215K -13,752 -4%
State Street
7
State Street
Massachusetts
$3.7M +$302K +19,304 +7%
Northern Trust
8
Northern Trust
Illinois
$3.22M -$147K -9,371 -4%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.2M +$165K +10,532 +13%
Group One Trading
10
Group One Trading
Illinois
$1.14M +$1.26M +80,341 +1,310%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$1.08M +$5.45K +348 +0.4%
HNB
12
Huntington National Bank
Ohio
$1.08M +$1.28M +82,000 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$1M -$516K -32,966 -30%
TCIM
14
TIAA CREF Investment Management
New York
$948K -$36.5K -2,330 -3%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$853K -$401K -25,638 -28%
CS
16
Credit Suisse
Switzerland
$781K +$249K +15,905 +37%
QBFM
17
QS Batterymarch Financial Management
New York
$634K +$755K +48,241 New
BIM
18
BlackRock Investment Management
Delaware
$601K -$141 -9 -0%
ProShare Advisors
19
ProShare Advisors
Maryland
$561K +$416K +26,618 +166%
Charles Schwab
20
Charles Schwab
California
$491K +$17.8K +1,140 +3%
KG
21
Killen Group
Pennsylvania
$454K
AllianceBernstein
22
AllianceBernstein
Tennessee
$427K -$23.2K -1,484 -4%
California State Teachers Retirement System (CalSTRS)
23
California State Teachers Retirement System (CalSTRS)
California
$394K
Citadel Advisors
24
Citadel Advisors
Florida
$367K -$93.1K -5,951 -18%
PCMI
25
Princeton Capital Management Inc
New Jersey
$365K +$21.9K +1,400 +5%

OSIR Hedge Fund Activity: Q1 2014 in Review

63 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2014, worth a combined $113M — down 10% from $126M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of OSIR and 7 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 23 added.

The largest buyer was Consonance Capital Management, adding an estimated $16.9M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $4.14M sold.

  • 63 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2014, down from 67 in Q4 2013.
  • Funds reported $113M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2014, down 10% quarter-over-quarter.
  • 7 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2014 and 10 closed out, a net change of -3 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2014 was Consonance Capital Management, an estimated $16.9M added.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2014 was Lord, Abbett & Co, an estimated $4.14M sold.

Based on aggregated 13F filings for Q1 2014.